{"filings":[{"id":609763,"accession_number":"0001193125-26-236929","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-05-22T20:15:20+00:00","items":["5.07"],"status":"ready","headline":"Waters shareholders re-elect all 11 directors, ratify PwC, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approx. 90.7M shares (92.4% of eligible) voted at May 21, 2026 annual meeting.","All 11 directors re-elected; Flemming Ornskov received 83.1M for, 3.96M against.","Ratification of PwC as auditor for FY 2026 passed with 84.8M for, 4.98M against.","Non-binding advisory vote on executive compensation approved 76.6M for, 10.7M against.","Votes on each proposal included broker non-votes totaling 3.39M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90493,"accession_number":"0001193125-26-204955","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q1 revenue $1.267B beats guidance; raises FY2026 adjusted EPS outlook to $14.40-$14.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total reported revenue of $1.267B exceeded guidance by $56M; GAAP EPS ($0.87) due to acquisition charges, Adjusted EPS $2.70 (+20% YoY).","Organic revenue grew 13% (11% constant currency), exceeding high end of guidance; driven by instrument and chemistry growth.","Acquired Biosciences & Diagnostic Solutions contributed $520M revenue from Feb 9 close, $40M above guidance.","Raising FY2026 organic constant currency growth guidance to 6.5%-8.0%, adjusted EPS to $14.40-$14.60.","Q2 2026 guidance: revenue $1.616B-$1.631B, adjusted EPS $2.95-$3.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":1267000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100045,"accession_number":"0001193125-26-119753","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Waters subsidiary issues $3.5B in senior notes across five tranches to repay DDTL","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issuer Augusta SpinCo completed offering of $3.5B senior notes: 4.321% due 2027, 4.398% 2029, 4.656% 2031, 4.945% 2033, 5.245% 2036.","Notes are fully and unconditionally guaranteed by Waters Corp and certain subsidiaries.","Proceeds used to repay $3.5B of indebtedness under delayed draw term loan incurred in February 2026.","Change of control triggers mandatory repurchase at 101% of principal plus accrued interest.","Underwriters include Barclays, Citigroup, J.P. Morgan, BofA Securities, and HSBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100044,"accession_number":"0001193125-26-107339","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.","BDS Business Q1 FY2026 net sales $766M (down 8% YoY from $834M); net income $49M vs $78M.","Operating income fell to $35M from $94M; includes $4M integration, restructuring & transaction costs.","Pro forma condensed combined financials as of Dec 31, 2025 and for FY2025 filed as Exhibit 99.4.","MD&A for fiscal years 2023-2025 and Q1 FY2026 provided; historical allocations may not reflect stand-alone costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100043,"accession_number":"0001193125-26-042819","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["1.01","2.01","2.03","5.02","7.01","9.01"],"status":"ready","headline":"Waters completes $4B combination with BD's Biosciences & Diagnostic Solutions; forms four divisions","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consummated spin-off and merger of BD's Biosciences & Diagnostic Solutions; BD shareholders received ~0.135 Waters shares per BD share, owning 39.2% of combined company.","SpinCo borrowed $4.0B term loan to fund cash payment to BD; Waters guaranteed the debt.","Claire M. Fraser, Ph.D. appointed to Waters Board, increasing size to 11.","New structure: four divisions - Analytical Sciences, Biosciences, Advanced Diagnostics, Materials Sciences.","Combined entity focused on high-volume testing in regulated applications; expects long-term value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100042,"accession_number":"0001193125-26-041897","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 2025 sales $932M (+7%), non-GAAP EPS $4.53 (+10%); BD deal closed; guides FY26 rev $6.4-6.5B, EPS $14.30-14.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $932M (+7% reported, +6% CC); GAAP EPS $3.77, non-GAAP EPS $4.53 (+10% YoY).","Q4 end-markets: Pharma +8%, Industrial +8%, Academic/Gov -2%; Instruments +3%, Recurring +10% (Chemistry +12% CC).","Full-year 2025 sales $3,165M (+7%); non-GAAP EPS $13.13 (+11% YoY).","Closes BD Biosciences & Diagnostic Solutions acquisition; acquired business adds ~$3.0B revenue in FY2026.","FY2026 guidance: organic CC growth 5.5%-7.0%, total rev $6.405B-$6.455B; non-GAAP EPS $14.30-$14.50 (+8.9%-10.4% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":10.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":3165286000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100041,"accession_number":"0001193125-26-024492","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Waters shareholders approve BD Biosciences combination; close expected Feb 9, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Approximately 99% of shares present at special meeting voted to approve share issuance for BD Biosciences deal.","Transaction expected to close on February 9, 2026, subject to remaining customary conditions.","IRS private letter ruling on tax consequences received; all required regulatory approvals secured.","Waters Q4 2025 earnings release and conference call rescheduled to February 9, 2026, in conjunction with close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100040,"accession_number":"0001193125-26-015384","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Waters supplements merger proxy after two stockholder lawsuits alleging omissions","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two lawsuits filed in NY Supreme Court (Carroll, Clark) claim proxy omits material information; demand letters also received.","Waters voluntarily adds multi-year financial projections (2025-2034) for standalone, advocacy, and SpinCo cases.","Barclays DCF analysis values Waters standalone at $20.9B-$24.7B equity range ($348-$411/share) using 9%-10% discount rate.","BDS Business enterprise value estimated at $16.8B-$19.7B standalone, $19.6B-$23.1B with synergies.","Special meeting of Waters stockholders to vote on merger remains January 27, 2026; Board continues recommendation FOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100039,"accession_number":"0001193125-26-010633","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters furnishes investor presentation at J.P. Morgan Conference; no financial details in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing furnishes investor presentation dated January 12, 2026 for J.P. Morgan Healthcare Conference.","Presentation cover indicates CEO Udit Batra presenting; content not included in filing excerpt.","Ongoing transaction with BD (spin-off of SpinCo) referenced; no new transaction details provided.","Form S-4 and definitive proxy previously filed and effective December 2025.","Unable to extract specific financial or operational updates from incomplete exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116386,"accession_number":"0001193125-25-263520","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q3 sales $800M (+8% YoY), non-GAAP EPS $3.40 (+16%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $800M, +8% as reported and constant currency, above guidance.","GAAP EPS $2.50; non-GAAP EPS $3.40, up 16% YoY, above guidance.","Pharma +11% cc; instruments +6%, recurring +9% cc; chemistry double-digit growth.","FY25 constant currency sales growth guidance raised to +6.7% to +7.3%; non-GAAP EPS raised to $13.05-$13.15.","Integration planning for BD Biosciences acquisition progressing; CEO confident in synergies."],"consensus_eps_estimate":null,"consensus_eps_actual":2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":799887000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132831,"accession_number":"0001193125-25-172076","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q2 sales $771M (+9% reported, +8% CC); GAAP EPS $2.47, non-GAAP $2.95; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $771M, up 9% reported and 8% constant currency vs $709M prior year.","GAAP EPS $2.47; non-GAAP EPS $2.95, up 12% YoY, above guidance mid-point.","Pharma segment grew 11% CC; Industrial +6%; Academic/Government declined 3%.","Raising FY2025 constant currency sales growth guidance to +5.5% to +7.5%; non-GAAP EPS $12.95-$13.05.","Q3 2025 guidance: constant currency sales growth +5.0% to +7.0%; non-GAAP EPS $3.15-$3.25."],"consensus_eps_estimate":null,"consensus_eps_actual":2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":771332000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132830,"accession_number":"0001193125-25-158796","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Waters to acquire BD's Biosciences & Diagnostic Solutions via Reverse Morris Trust","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Waters shareholders to own ~60.8% and former SpinCo shareholders ~39.2% of combined company post-merger.","SpinCo will pay BD $4.0B cash prior to distribution; Waters arranged $1.8B bridge loan for potential special dividend.","Transaction unanimously approved by both boards; expected close by July 13, 2026, subject to regulatory and shareholder approvals.","Waters to pay BD $733M termination fee under certain circumstances if deal fails.","Post-closing board will have 11-12 members, with 1-2 appointed by BD after consultation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132829,"accession_number":"0001193125-25-158409","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters to combine with BD's Biosciences & Diagnostic Solutions in $17.5B deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at ~$17.5B; Waters shareholders own ~60.8%, BD shareholders ~39.2% of combined co.","Pro forma 2025 revenue ~$6.5B, adjusted EBITDA ~$2.0B; expected accretive to adj EPS in Y1.","Targets mid-to-high single-digit revenue growth and mid-teens adj EPS growth annually 2025-2030.","Anticipates ~$345M annualized EBITDA synergies by 2030: $200M cost by Y3, $290M revenue by Y5.","Closing expected around end of Q1 2026, subject to regulatory approvals and Waters shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149385,"accession_number":"0001193125-25-130641","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp amends credit facility; removes $200M term loan, retains $1.8B revolver through 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Removed existing $200M term loan; retained $1.8B senior unsecured revolving credit facility maturing May 22, 2030.","May request up to $750M incremental commitments (total cap $2.55B); up to $50M available for letters of credit.","Interest spreads: Term SOFR + 80–112.5 bps; facility fee 7.5–22.5 bps based on leverage or debt ratings.","Leverage covenant max 3.50x (can rise to 4.25x for acquisitions ≥$500M cash consideration).","JPMorgan Chase remains administrative agent; subsidiaries guarantee obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149384,"accession_number":"0001193125-25-125877","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters Corp annual meeting elects all 10 directors, approves compensation and ESPP amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approximately 94.12% of shares represented; all 10 director nominees re-elected.","Ratification of PwC as auditor for fiscal 2025 approved (51.7M for vs 3.4M against).","Non-binding advisory vote on executive compensation passed (44.7M for, 9.6M against).","Amended and Restated 2009 Employee Stock Purchase Plan approved (54.3M for).","Broker non-votes of ~1.65M recorded on director election and advisory compensation votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149383,"accession_number":"0001193125-25-113232","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q1 2025 results announced; financial details not disclosed in excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Quarter ended March 29, 2025 results released May 6, 2025.","Press release furnished as Exhibit 99.1 but full text not available.","Investor contact: Caspar Tudor, Head of IR.","No specific revenue, EPS, or segment data provided."],"consensus_eps_estimate":4.5523,"consensus_eps_actual":2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":662000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168450,"accession_number":"0001193125-25-024730","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 sales $873M beat guidance; non-GAAP EPS $4.10 up 13% YoY; FY2025 EPS guide $12.70-$13.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $873M, +6% reported / +8% constant currency; exceeded high-end of guidance range.","Non-GAAP EPS $4.10 (+13% YoY); GAAP EPS $3.88; FX headwind ~9% in Q4.","Full-year sales $2,958M (flat); non-GAAP EPS $11.86 (+1%); operating cash flow $762M; free cash flow $744M (25% of sales).","FY2025 guidance: constant currency sales growth +4.5%–7.0%; non-GAAP EPS $12.70–$13.00; Q1 non-GAAP EPS $2.17–$2.25.","Pharma sales +10% constant currency; instruments +8%, recurring +9% constant currency in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":10.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":2958387000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168449,"accession_number":"0001193125-25-005378","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Waters to present at J.P. Morgan Healthcare Conference on Jan 13, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Udit Batra will present at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.","Presentation includes high-level commentary on business performance, no detailed financial results disclosed.","Transcript will be available on Waters website in the Investors section under Events & Presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185580,"accession_number":"0001193125-24-249066","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q3 sales $740M (+4% YoY); GAAP EPS $2.71, non-GAAP $2.93; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $740M (+4% as reported and constant currency); GAAP EPS $2.71, non-GAAP EPS $2.93, beating guidance.","Instrument system sales returned to growth (+1%); recurring revenues up 6% as reported (7% constant currency).","FY 2024 organic constant currency sales growth guidance raised to -0.9% to -0.3%; non-GAAP EPS raised to $11.67-$11.87.","Q4 2024 guidance: constant currency sales growth +5% to +7%; non-GAAP EPS $3.90-$4.10."],"consensus_eps_estimate":null,"consensus_eps_actual":2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":740305000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185579,"accession_number":"0001193125-24-249455","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K/A","filed_at":"2024-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Waters appoints Heather Knight to Nominating and Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Knight was appointed to the Board effective August 14, 2024 per prior 8-K.","On October 31, 2024, the Board named Knight to the Nominating and Corporate Governance Committee, effective immediately.","The committee appointment is a routine governance update with no financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202158,"accession_number":"0001193125-24-200650","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Waters Corporation appoints Heather Knight to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Heather Knight effective Aug 14, 2024; Board size increased from 9 to 10.","Knight is EVP and Group President, Medical Products and Therapies at Baxter International.","Initial equity grant valued at $91,666 (50% RSU, 50% option), vesting on first anniversary.","Prorated cash retainer of $54,130 until 2025 AGM; standard non-employee director compensation.","Knight brings nearly three decades of global pharma and med device leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202157,"accession_number":"0001193125-24-189455","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters reports Q2 2024 results; full financial details unavailable from excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release announces results for the quarter ended June 29, 2024, but full text is not provided.","No specific revenue, EPS, or segment figures can be extracted from the submitted text.","Investors should consult the complete press release for material financial information."],"consensus_eps_estimate":null,"consensus_eps_actual":2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":708529000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202156,"accession_number":"0001193125-24-180722","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Waters Corp enters $200M private shelf note facility with NYL Investors","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $200M senior promissory notes; maturity up to 15 years per issuance.","Proceeds for general corporate purposes: refinancing, share repurchases, capex, acquisitions.","Financial covenants: max leverage ratio 3.50:1.00, min interest coverage 3.50:1.00.","Shelf facility with no commitment; NYL may decline purchases; issuance period through Feb 2026.","Guaranteed by certain subsidiaries under a Guarantee Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218214,"accession_number":"0001193125-24-147025","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Waters shareholders elect all 9 directors, ratify PwC, approve say-on-pay and officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 54.3M shares (91.63%) present; all 9 director nominees elected with votes ranging from 41.8M to 52.4M for.","Ratification of PricewaterhouseCoopers as auditor for FY2024 approved: 50.4M for, 3.9M against.","Non-binding advisory vote on named executive officer compensation passed: 42.0M for, 10.7M against.","Amendment to certificate of incorporation for officer exculpation under Delaware law approved: 48.7M for, 3.9M against.","Director Flemming Ornskov received the lowest support: 41.8M for, 9.7M against, 1.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218213,"accession_number":"0001193125-24-132549","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Corp reports Q1 2024 results; press release text truncated, no specifics available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced Q1 2024 results on May 7, 2024, but the attached press release text is incomplete.","Quarter ended March 30, 2024; key financial data (revenue, EPS) not included in provided document.","Further details are expected in the full press release referenced as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":636839000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238184,"accession_number":"0001193125-24-024758","cik":1000697,"company_name":"WATERS CORP /DE/","ticker":"WAT","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Waters Q4 2023 sales $819M (-4.5%); FY guidance organic growth -0.5% to +1.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $3.65, non-GAAP $3.62 (at high end of guidance); YoY decline from $3.84.","Full-year 2023 sales $2,956M (-0.5% as reported); non-GAAP EPS $11.75 vs $12.02 prior year.","Gross margin expanded 160bps to 59.6%; adjusted operating margin expanded 70bps to 30.9%.","China Q4 sales declined almost 40%; pharma sales down 6% as reported.","Q1 2024 guidance: organic sales -11% to -9%; non-GAAP EPS $2.05-$2.15."],"consensus_eps_estimate":null,"consensus_eps_actual":10.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2956416000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32721420000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}